Pegademase

DB00061

biotech approved

Deskripsi

Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) plasma adenosine deaminase elimination half-life is 3 to >6 days
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Time to peak for plasma adenosine deaminase is 2 to 3 days

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

37 Data
Pentostatin The therapeutic efficacy of Pentostatin can be decreased when used in combination with Pegademase.
Peginterferon alfa-2a The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2a.
Pegfilgrastim The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegfilgrastim.
Peginterferon alfa-2b The therapeutic efficacy of Pegademase can be decreased when used in combination with Peginterferon alfa-2b.
Pegaspargase The therapeutic efficacy of Pegademase can be decreased when used in combination with Pegaspargase.
Pegvisomant The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Pegademase.
Propylene glycol The therapeutic efficacy of Propylene glycol can be decreased when used in combination with Pegademase.
Heptaethylene glycol The therapeutic efficacy of Heptaethylene glycol can be decreased when used in combination with Pegademase.
Pegaptanib The therapeutic efficacy of Pegaptanib can be decreased when used in combination with Pegademase.
Egaptivon pegol The therapeutic efficacy of Egaptivon pegol can be decreased when used in combination with Pegademase.
PEG-uricase The therapeutic efficacy of PEG-uricase can be decreased when used in combination with Pegademase.
Peginterferon alfacon-1 The therapeutic efficacy of Peginterferon alfacon-1 can be decreased when used in combination with Pegademase.
GlycoPEG-GCSF The therapeutic efficacy of GlycoPEG-GCSF can be decreased when used in combination with Pegademase.
Pegnivacogin The therapeutic efficacy of Pegnivacogin can be decreased when used in combination with Pegademase.
Pegpleranib The therapeutic efficacy of Pegpleranib can be decreased when used in combination with Pegademase.
Pegsunercept The therapeutic efficacy of Pegsunercept can be decreased when used in combination with Pegademase.
Polidocanol The therapeutic efficacy of Polidocanol can be decreased when used in combination with Pegademase.
Peginesatide The therapeutic efficacy of Peginesatide can be decreased when used in combination with Pegademase.
Certolizumab pegol The therapeutic efficacy of Certolizumab pegol can be decreased when used in combination with Pegademase.
Methoxy polyethylene glycol-epoetin beta The therapeutic efficacy of Methoxy polyethylene glycol-epoetin beta can be decreased when used in combination with Pegademase.
Peginterferon beta-1a The therapeutic efficacy of Peginterferon beta-1a can be decreased when used in combination with Pegademase.
Pegloticase The therapeutic efficacy of Pegloticase can be decreased when used in combination with Pegademase.
Polyethylene glycol The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Pegademase.
Antihemophilic factor (recombinant), PEGylated The therapeutic efficacy of Antihemophilic factor (recombinant), PEGylated can be decreased when used in combination with Pegademase.
Insulin peglispro The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Pegademase.
Eptacog alfa pegol (activated) The therapeutic efficacy of Eptacog alfa pegol (activated) can be decreased when used in combination with Pegademase.
Olaptesed Pegol The therapeutic efficacy of Olaptesed Pegol can be decreased when used in combination with Pegademase.
Abicipar Pegol The therapeutic efficacy of Abicipar Pegol can be decreased when used in combination with Pegademase.
Lexaptepid pegol The therapeutic efficacy of Lexaptepid pegol can be decreased when used in combination with Pegademase.
Cepeginterferon alfa-2B The therapeutic efficacy of Cepeginterferon alfa-2B can be decreased when used in combination with Pegademase.
Pegvaliase The therapeutic efficacy of Pegvaliase can be decreased when used in combination with Pegademase.
Pegamotecan The therapeutic efficacy of Pegamotecan can be decreased when used in combination with Pegademase.
Lipegfilgrastim The therapeutic efficacy of Lipegfilgrastim can be decreased when used in combination with Pegademase.
Nonacog beta pegol The therapeutic efficacy of Nonacog beta pegol can be decreased when used in combination with Pegademase.
Damoctocog alfa pegol The therapeutic efficacy of Damoctocog alfa pegol can be decreased when used in combination with Pegademase.
Elapegademase The therapeutic efficacy of Elapegademase can be decreased when used in combination with Pegademase.
Rurioctocog alfa pegol The therapeutic efficacy of Rurioctocog alfa pegol can be decreased when used in combination with Pegademase.

Target Protein

Adenosine
Growth factor receptor-bound protein 2 GRB2

Referensi & Sumber

Synthesis reference: Paul Skonezny, "Process for preparing dideoxyinosine using adenosine deaminase enzyme." U.S. Patent US20040175804, issued September 09, 2004.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Adagen
    Injection, solution • 250 [iU]/1mL • Intramuscular • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul